{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:48:46Z","timestamp":1791838126511,"version":"4.3.4"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH NIAID","award":["2-R01AI129265-06"],"award-info":[{"award-number":["2-R01AI129265-06"]}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review examines the growing need for alternative technologies to address the resurgence of syphilis, particularly its congenital and late-stage manifestations. It explores current treatment paradigms, highlights the limitations of penicillin, and evaluates emerging evidence on new therapies and diagnostics to inform future strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>\n                      Recent breakthroughs in\n                      <jats:italic>Treponema pallidum<\/jats:italic>\n                      culture techniques have enabled antibiotic susceptibility testing, expanding knowledge on both established and emerging treatment options. Alternatives like ceftriaxone, doxycycline, cefixime, and dalbavancin show promise, with other candidates in trials, though evidence is limited beyond early-stage syphilis. Shortened penicillin regimens also challenge historical assumptions about treatment duration. Advanced molecular diagnostics may complement currently limited serologic monitoring to improve evaluations in healthcare and research.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>While penicillin remains effective, its limitations necessitate alternatives. Emerging antibiotics and improved diagnostics offer opportunities to simplify treatment and enhance care. Future robust trials should validate new treatments, refine dosing strategies, and integrate innovative diagnostics, particularly including underserved and vulnerable populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11904-025-00725-4","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T20:10:41Z","timestamp":1741810241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Expanding Horizons in Syphilis Treatment: Challenges, Advances, and Opportunities for Alternative Antibiotics"],"prefix":"10.1007","volume":"22","author":[{"given":"Diana D.","family":"Villarreal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3762-1620","authenticated-orcid":false,"given":"Chibuzor M.","family":"Babalola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"46","key":"725_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.15585\/mmwr.mm7246e1","volume":"72","author":"R McDonald","year":"2023","unstructured":"McDonald R, O\u2019Callaghan K, Torrone E, Barbee L, Grey J, Jackson D, et al. Vital Signs: Missed Opportunities for Preventing Congenital Syphilis - United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(46):1269\u201374.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"725_CR2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1186\/s12889-023-15510-4","volume":"23","author":"YT Tao","year":"2023","unstructured":"Tao YT, Gao TY, Li HY, Ma YT, Li HJ, Xian-Yu CY, et al. Global, regional, and national trends of syphilis from 1990 to 2019: the 2019 global burden of disease study. BMC Public Health. 2023;23(1):754.","journal-title":"BMC Public Health"},{"issue":"9","key":"725_CR3","first-page":"725","volume":"331","author":"E Harris","year":"2024","unstructured":"Harris E. \u201cAlarming Trend\u201d Persists as Syphilis Cases Swelled in the US in 2022. JAMA. 2024;331(9):725.","journal-title":"JAMA"},{"issue":"3","key":"725_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJMra2202762","volume":"390","author":"IA Stafford","year":"2024","unstructured":"Stafford IA, Workowski KA, Bachmann LH. Syphilis Complicating Pregnancy and Congenital Syphilis. N Engl J Med. 2024;390(3):242\u201353.","journal-title":"N Engl J Med"},{"issue":"11","key":"725_CR5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/pathogens11111278","volume":"11","author":"C Auriti","year":"2022","unstructured":"Auriti C, Bucci S, De Rose DU, Coltella L, Santisi A, Martini L, et al. Maternal-Fetal Infections Cytomegalovirus. Pathogens. 2022;11(11):1278.","journal-title":"Pathogens."},{"issue":"4","key":"725_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1473-3099(08)70065-3","volume":"8","author":"KA Fenton","year":"2008","unstructured":"Fenton KA, Breban R, Vardavas R, Okano JT, Martin T, Aral S, et al. Infectious syphilis in high-income settings in the 21st century. Lancet Infect Dis. 2008;8(4):244\u201353.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"725_CR7","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1093\/cid\/ciaa1716","volume":"72","author":"J Ueleres Braga","year":"2021","unstructured":"Ueleres Braga J, Araujo RS, de Souza ASS. The Shortage of Benzathine Penicillin and Its Impact on Congenital Syphilis Incidence: An Ecologic Study in the City of Rio de Janeiro. Clin Infect Dis. 2021;72(5):e79\u201387.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"725_CR8","doi-asserted-by":"publisher","first-page":"559-A","DOI":"10.2471\/BLT.16.173310","volume":"94","author":"MM Taylor","year":"2016","unstructured":"Taylor MM, Zhang X, Nurse-Findlay S, Hedman L, Kiarie J. The amount of penicillin needed to prevent mother-to-child transmission of syphilis. Bull World Health Organ. 2016;94(8):559-A.","journal-title":"Bull World Health Organ."},{"issue":"4","key":"725_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"KA Workowski","year":"2021","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1\u2013187.","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"725_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7301a1","volume":"73","author":"JR Papp","year":"2024","unstructured":"Papp JR, Park IU, Fakile Y, Pereira L, Pillay A, Bolan GA. CDC Laboratory Recommendations for Syphilis Testing, United States, 2024. MMWR Recomm Rep. 2024;73(1):1\u201332.","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"725_CR11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1071\/SH20043","volume":"17","author":"R Harjanto","year":"2020","unstructured":"Harjanto R, Smith DE, Barratt H, Kelly M, Chan D, Furner V, et al. Utility of rapid plasmin reagin titres in assessing treatment response and re-infection for infectious syphilis. Sex Health. 2020;17(4):330\u20136.","journal-title":"Sex Health"},{"issue":"3","key":"725_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.7326\/0003-4819-104-3-368","volume":"104","author":"G Hart","year":"1986","unstructured":"Hart G. Syphilis tests in diagnostic and therapeutic decision making. Ann Intern Med. 1986;104(3):368\u201376.","journal-title":"Ann Intern Med"},{"issue":"2","key":"725_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cmi.2019.06.004","volume":"26","author":"LR Lin","year":"2020","unstructured":"Lin LR, Zhu XZ, Liu D, Liu LL, Tong ML, Yang TC. Are nontreponemal tests suitable for monitoring syphilis treatment efficacy? Evidence from rabbit infection models. Clin Microbiol Infect. 2020;26(2):240\u20136.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"725_CR14","doi-asserted-by":"publisher","first-page":"e0292044","DOI":"10.1371\/journal.pone.0292044","volume":"18","author":"K Ikeuchi","year":"2023","unstructured":"Ikeuchi K, Fukushima K, Tanaka M, Yajima K, Saito M, Imamura A. Changes in rapid plasma reagin titers in patients with syphilis before and after treatment: A retrospective cohort study in an HIV\/AIDS referral hospital in Tokyo. PLoS ONE. 2023;18(9):e0292044.","journal-title":"PLoS ONE"},{"issue":"3","key":"725_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0021-9681(55)90139-9","volume":"2","author":"EG Clark","year":"1955","unstructured":"Clark EG, Danbolt N. The Oslo study of the natural history of untreated syphilis; an epidemiologic investigation based on a restudy of the Boeck-Bruusgaard material; a review and appraisal. J Chronic Dis. 1955;2(3):311\u201344.","journal-title":"J Chronic Dis"},{"issue":"27","key":"725_CR16","doi-asserted-by":"publisher","first-page":"13498","DOI":"10.1073\/pnas.1904170116","volume":"116","author":"BL Jutras","year":"2019","unstructured":"Jutras BL, Lochhead RB, Kloos ZA, Biboy J, Strle K, Booth CJ, et al. peptidoglycan is a persistent antigen in patients with Lyme arthritis. Proc Natl Acad Sci U S A. 2019;116(27):13498\u2013507.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"725_CR17","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1111\/j.1755-5949.2010.00183.x","volume":"16","author":"KG Ghanem","year":"2010","unstructured":"Ghanem KG. REVIEW: Neurosyphilis: A historical perspective and review. CNS Neurosci Ther. 2010;16(5):e157\u201368.","journal-title":"CNS Neurosci Ther"},{"key":"725_CR18","unstructured":"WHO. Guidelines for the treatment of\u00a0Treponema pallidum (Syphilis). Geneva: World Health Organization. 2016."},{"issue":"1","key":"725_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.1947.02880010003001","volume":"133","author":"TH Sternberg","year":"1947","unstructured":"Sternberg TH, Leifer W. Treatment of early syphilis with penicillin. J Am Med Assoc. 1947;133(1):1\u20135.","journal-title":"J Am Med Assoc"},{"issue":"6","key":"725_CR20","first-page":"1087","volume":"15","author":"CA Smith","year":"1956","unstructured":"Smith CA, Kamp M, Olansky S, Price EV. Benzathine penicillin G in the treatment of syphilis. Bull World Health Organ. 1956;15(6):1087\u201396.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"725_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1001\/jama.1947.02880010012003","volume":"133","author":"RV Platou","year":"1947","unstructured":"Platou RV, Hill AJ. Early congenital syphilis; treatment of two hundred and fifty-two patients with penicillin. J Am Med Assoc. 1947;133(1):10\u20136.","journal-title":"J Am Med Assoc"},{"issue":"3","key":"725_CR22","first-page":"143","volume":"39","author":"FJ Jefferiss","year":"1963","unstructured":"Jefferiss FJ, Willcox RR. Treatment, OF EARLY SYPHILIS WITH PENICILLIN ALONE. Br J Vener Dis. 1963;39(3):143\u20138.","journal-title":"Br J Vener Dis"},{"issue":"5","key":"725_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/archderm.1973.01620260013003","volume":"108","author":"RD Durst","year":"1973","unstructured":"Durst RD, Sibulkin D, Trunnell TN, Allyn B. Dose-related seroreversal in syphilis. Arch Dermatol. 1973;108(5):663\u20134.","journal-title":"Arch Dermatol"},{"issue":"3","key":"725_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0190-9622(86)70063-7","volume":"14","author":"NJ Fiumara","year":"1986","unstructured":"Fiumara NJ. Treatment of primary and secondary syphilis: serologic response. J Am Acad Dermatol. 1986;14(3):487\u201391.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"725_CR25","first-page":"120","volume":"68","author":"S Talwar","year":"1992","unstructured":"Talwar S, Tutakne MA, Tiwari VD. VDRL titres in early syphilis before and after treatment. Genitourin Med. 1992;68(2):120\u20132.","journal-title":"Genitourin Med"},{"issue":"5","key":"725_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJM199707313370504","volume":"337","author":"RT Rolfs","year":"1997","unstructured":"Rolfs RT, Joesoef MR, Hendershot EF, Rompalo AM, Augenbraun MH, Chiu M, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med. 1997;337(5):307\u201314.","journal-title":"N Engl J Med."},{"key":"725_CR27","first-page":"204993612412659","volume":"11","author":"A Clarkson-During","year":"2024","unstructured":"Clarkson-During A, Almirol E, Eller D, Hazra A, Stanford KA. Risk factors for treatment non-completion among patients with syphilis. Ther Adv Infect Dis. 2024;11:20499361241265940.","journal-title":"Ther Adv Infect Dis"},{"issue":"18","key":"725_CR28","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1001\/jama.2014.13259","volume":"312","author":"ME Clement","year":"2014","unstructured":"Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review. JAMA. 2014;312(18):1905\u201317.","journal-title":"JAMA"},{"issue":"4","key":"725_CR29","doi-asserted-by":"publisher","first-page":"ofae142","DOI":"10.1093\/ofid\/ofae142","volume":"11","author":"GY Callado","year":"2024","unstructured":"Callado GY, Gutfreund MC, Pardo I, Hsieh MK, Lin V, Sampson MM, et al. Syphilis Treatment: Systematic Review and Meta-Analysis Investigating Nonpenicillin Therapeutic Strategies. Open Forum Infect Dis. 2024;11(4):ofae142.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"725_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/OLQ.0000000000001983","volume":"51","author":"GY Callado","year":"2024","unstructured":"Callado GY, Pardo I, Gutfreund MC, Deliberato RO, Holubar M, Salinas JL, et al. Insights Into Treatment Alternatives for Neurosyphilis: Systematic Literature Review and Meta-Analysis. Sex Transm Dis. 2024;51(10):641\u20137.","journal-title":"Sex Transm Dis"},{"issue":"5","key":"725_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/0002-9343(92)90574-U","volume":"93","author":"ME Dowell","year":"1992","unstructured":"Dowell ME, Ross PG, Musher DM, Cate TR, Baughn RE. Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeficiency virus. Am J Med. 1992;93(5):481\u20138.","journal-title":"Am J Med"},{"key":"725_CR32","unstructured":"Wang S, Gu W, Cao Y, Zheng H, Zhang L, Guo X, et al. Comparison of the clinical efficacy of penicillin and ceftriaxone sodium in the treatment of neurosyphilis with psychiatric symptoms. World J Psychiatry Ment Health Res.\u00a02022;5:1030."},{"issue":"5","key":"725_CR33","first-page":"CD011399","volume":"5","author":"D Buitrago-Garcia","year":"2019","unstructured":"Buitrago-Garcia D, Mart\u00ed-Carvajal AJ, Jimenez A, Conterno LO, Pardo R. Antibiotic therapy for adults with neurosyphilis. Cochrane Database Syst Rev. 2019;5(5):CD011399.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"725_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.medmal.2011.10.003","volume":"42","author":"KC Psomas","year":"2012","unstructured":"Psomas KC, Brun M, Causse A, Atoui N, Reynes J, Le Moing V. Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis. Med Mal Infect. 2012;42(1):15\u20139.","journal-title":"Med Mal Infect"},{"issue":"5","key":"725_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/095646240401500511","volume":"15","author":"NH Smith","year":"2004","unstructured":"Smith NH, Musher DM, Huang DB, Rodriguez PS, Dowell ME, Ace W, et al. Response of HIV-infected patients with asymptomatic syphilis to intensive intramuscular therapy with ceftriaxone or procaine penicillin. Int J STD AIDS. 2004;15(5):328\u201332.","journal-title":"Int J STD AIDS"},{"issue":"10","key":"725_CR36","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/S1473-3099(20)30857-4","volume":"21","author":"T Bettuzzi","year":"2021","unstructured":"Bettuzzi T, Jourdes A, Robineau O, Alcaraz I, Manda V, Molina JM, et al. Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study. Lancet Infect Dis. 2021;21(10):1441\u20137.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"725_CR37","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1086\/313725","volume":"30","author":"CM Marra","year":"2000","unstructured":"Marra CM, Boutin P, McArthur JC, Hurwitz S, Simpson PA, Haslett JA, et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2000;30(3):540\u20134.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"725_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/2047-783X-16-2-47","volume":"16","author":"P Spornraft-Ragaller","year":"2011","unstructured":"Spornraft-Ragaller P, Abraham S, Lueck C, Meurer M. Response of HIV-infected patients with syphilis to therapy with penicillin or intravenous ceftriaxone. Eur J Med Res. 2011;16(2):47\u201351.","journal-title":"Eur J Med Res"},{"issue":"10","key":"725_CR39","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/cid\/cix611","volume":"65","author":"Y Cao","year":"2017","unstructured":"Cao Y, Su X, Wang Q, Xue H, Zhu X, Zhang C, et al. A Multicenter Study Evaluating Ceftriaxone and Benzathine Penicillin G as Treatment Agents for Early Syphilis in Jiangsu. China Clin Infect Dis. 2017;65(10):1683\u20138.","journal-title":"China Clin Infect Dis"},{"issue":"2","key":"725_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000238661","volume":"35","author":"H Sch\u00f6fer","year":"1989","unstructured":"Sch\u00f6fer H, Vogt HJ, Milbradt R. Ceftriaxone for the treatment of primary and secondary syphilis. Chemotherapy. 1989;35(2):140\u20135.","journal-title":"Chemotherapy"},{"issue":"4","key":"725_CR41","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/infdis\/158.4.881","volume":"158","author":"EW Hook","year":"1988","unstructured":"Hook EW, Roddy RE, Handsfield HH. Ceftriaxone therapy for incubating and early syphilis. J Infect Dis. 1988;158(4):881\u20134.","journal-title":"J Infect Dis"},{"issue":"2","key":"725_CR42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/00007435-198704000-00013","volume":"14","author":"TT Moorthy","year":"1987","unstructured":"Moorthy TT, Lee CT, Lim KB, Tan T. Ceftriaxone for treatment of primary syphilis in men: a preliminary study. Sex Transm Dis. 1987;14(2):116\u20138.","journal-title":"Sex Transm Dis"},{"key":"725_CR43","doi-asserted-by":"crossref","unstructured":"Girometti N, Junejo MH, Nugent D, McOwan A, Whitlock G, Group DSC. Clinical and serological outcomes in patients treated with oral doxycycline for early neurosyphilis. J Antimicrob Chemother. 2021;76(7):1916-9","DOI":"10.1093\/jac\/dkab100"},{"issue":"6","key":"725_CR44","doi-asserted-by":"publisher","first-page":"e14025","DOI":"10.1111\/dth.14025","volume":"33","author":"Y Li","year":"2020","unstructured":"Li Y, Jiang G. Azithromycin vs penicillin G benzathine for early syphilis: A meta-analysis of randomized controlled trials. Dermatol Ther. 2020;33(6):e14025.","journal-title":"Dermatol Ther"},{"issue":"6","key":"725_CR45","doi-asserted-by":"publisher","first-page":"e0297722","DOI":"10.1128\/spectrum.02977-22","volume":"10","author":"M Liu","year":"2022","unstructured":"Liu M, Fan Y, Chen J, Yang J, Gao L, Wu X, et al. Efficacy and Safety of Treatments for Different Stages of Syphilis: a Systematic Review and Network Meta-Analysis of Randomized Controlled Trials and Observational Studies. Microbiol Spectr. 2022;10(6):e0297722.","journal-title":"Microbiol Spectr"},{"issue":"2","key":"725_CR46","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3855\/jidc.3013","volume":"8","author":"J Li","year":"2014","unstructured":"Li J, Zheng HY. Early syphilis: serological treatment response to doxycycline\/tetracycline versus benzathine penicillin. J Infect Dev Ctries. 2014;8(2):228\u201332.","journal-title":"J Infect Dev Ctries"},{"issue":"10","key":"725_CR47","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.amjmed.2008.04.042","volume":"121","author":"T Wong","year":"2008","unstructured":"Wong T, Singh AE, De P. Primary syphilis: serological treatment response to doxycycline\/tetracycline versus benzathine penicillin. Am J Med. 2008;121(10):903\u20138.","journal-title":"Am J Med"},{"issue":"6","key":"725_CR48","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1086\/500406","volume":"42","author":"KG Ghanem","year":"2006","unstructured":"Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis. 2006;42(6):e45\u20139.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"725_CR49","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jama.1972.03200180015003","volume":"221","author":"AL Schroeter","year":"1972","unstructured":"Schroeter AL, Lucas JB, Price EV, Falcone VH. Treatment for early syphilis and reactivity of serologic tests. JAMA. 1972;221(5):471\u20136.","journal-title":"JAMA"},{"issue":"1","key":"725_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/QAD.0000000000001975","volume":"33","author":"MB Antonio","year":"2019","unstructured":"Antonio MB, Cuba GT, Vasconcelos RP, Alves APPS, da Silva BO, Avelino-Silva VI. Natural experiment of syphilis treatment with doxycycline or benzathine penicillin in HIV-infected patients. AIDS. 2019;33(1):77\u201381.","journal-title":"AIDS"},{"issue":"6","key":"725_CR51","first-page":"807","volume":"96","author":"K Salado-Rasmussen","year":"2016","unstructured":"Salado-Rasmussen K, Hoffmann S, Cowan S, Jensen JS, Benfield T, Gerstoft J, et al. Serological Response to Treatment of Syphilis with Doxycycline Compared with Penicillin in HIV-infected Individuals. Acta Derm Venereol. 2016;96(6):807\u201311.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"725_CR52","first-page":"107","volume":"25","author":"H Xiao","year":"2017","unstructured":"Xiao H, Liu D, Li Z, Zheng R, Hou J, Zhang S, et al. Comparison of Doxycycline and Benzathine Penicillin G for the Treatment of Early Syphilis. Acta Dermatovenerol Croat. 2017;25(2):107\u201311.","journal-title":"Acta Dermatovenerol Croat"},{"issue":"10","key":"725_CR53","doi-asserted-by":"publisher","first-page":"e109813","DOI":"10.1371\/journal.pone.0109813","volume":"9","author":"JC Tsai","year":"2014","unstructured":"Tsai JC, Lin YH, Lu PL, Shen NJ, Yang CJ, Lee NY, et al. Comparison of serological response to doxycycline versus benzathine penicillin G in the treatment of early syphilis in HIV-infected patients: a multi-center observational study. PLoS ONE. 2014;9(10):e109813.","journal-title":"PLoS ONE"},{"issue":"8","key":"725_CR54","doi-asserted-by":"publisher","first-page":"e15586","DOI":"10.1111\/dth.15586","volume":"35","author":"C Zengarini","year":"2022","unstructured":"Zengarini C, Carpanese MA, Vara G, Conni A, Piraccini BM, Gaspari V. Analysis of serological treatment response to doxycycline versus benzathine penicillin in syphilis infections, a retrospective single-center study. Dermatol Ther. 2022;35(8):e15586.","journal-title":"Dermatol Ther"},{"issue":"3","key":"725_CR55","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/01.olq.0000204506.06551.5f","volume":"33","author":"CM Long","year":"2006","unstructured":"Long CM, Klausner JD, Leon S, Jones FR, Giron M, Cuadros J, et al. Syphilis treatment and HIV infection in a population-based study of persons at high risk for sexually transmitted disease\/HIV infection in Lima. Peru Sex Transm Dis. 2006;33(3):151\u20135.","journal-title":"Peru Sex Transm Dis"},{"issue":"3","key":"725_CR56","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1517\/14740338.2016.1133584","volume":"15","author":"R Cross","year":"2016","unstructured":"Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood\u2013time to rebuild its reputation? Expert Opin Drug Saf. 2016;15(3):367\u201382.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"725_CR57","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/cid\/ciad278","volume":"77","author":"N Ando","year":"2023","unstructured":"Ando N, Mizushima D, Omata K, Nemoto T, Inamura N, Hiramoto S, et al. Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled. Non-Inferiority Trial Clin Infect Dis. 2023;77(5):779\u201387.","journal-title":"Non-Inferiority Trial Clin Infect Dis"},{"issue":"3","key":"725_CR58","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/sextrans-2020-054823","volume":"98","author":"K Ikeuchi","year":"2022","unstructured":"Ikeuchi K, Fukushima K, Tanaka M, Yajima K, Imamura A. Clinical efficacy and tolerability of 1.5 g\/day oral amoxicillin therapy without probenecid for the treatment of syphilis. Sex Transm Infect. 2022;98(3):173\u20137.","journal-title":"Sex Transm Infect"},{"key":"725_CR59","first-page":"204993612311927","volume":"10","author":"M Inada","year":"2023","unstructured":"Inada M, Ando N, Mizushima D, Kikuchi Y, Gatanaga H, Oka S. Effect of unintended short-term 3.0 g\/day amoxicillin and probenecid treatment for early syphilis on patients with HIV-1 infection. Ther Adv Infect Dis. 2023;10:20499361231192776.","journal-title":"Ther Adv Infect Dis."},{"issue":"5","key":"725_CR60","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3201\/eid2305.161936","volume":"23","author":"Y Katanami","year":"2017","unstructured":"Katanami Y, Hashimoto T, Takaya S, Yamamoto K, Kutsuna S, Takeshita N, et al. Amoxicillin and Ceftriaxone as Treatment Alternatives to Penicillin for Maternal Syphilis. Emerg Infect Dis. 2017;23(5):827\u20139.","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"725_CR61","first-page":"359","volume":"61","author":"RE Morrison","year":"1985","unstructured":"Morrison RE, Harrison SM, Tramont EC. Oral amoxycillin, an alternative treatment for neurosyphilis. Genitourin Med. 1985;61(6):359\u201362.","journal-title":"Genitourin Med"},{"issue":"2","key":"725_CR62","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/cid\/civ270","volume":"61","author":"R Tanizaki","year":"2015","unstructured":"Tanizaki R, Nishijima T, Aoki T, Teruya K, Kikuchi Y, Oka S, et al. High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection. Clin Infect Dis. 2015;61(2):177\u201383.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"725_CR63","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1177\/030006057900700612","volume":"7","author":"Y Onoda","year":"1979","unstructured":"Onoda Y. Clinical evaluation of amoxycillin in the treatment of syphilis. J Int Med Res. 1979;7(6):539\u201345.","journal-title":"J Int Med Res"},{"issue":"6","key":"725_CR64","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3201\/eid2606.191300","volume":"26","author":"T Nishijima","year":"2020","unstructured":"Nishijima T, Kawana K, Fukasawa I, Ishikawa N, Taylor MM, Mikamo H, et al. Effectiveness and Tolerability of Oral Amoxicillin in Pregnant Women with Active Syphilis, Japan, 2010\u20132018. Emerg Infect Dis. 2020;26(6):1192\u2013200.","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"725_CR65","doi-asserted-by":"publisher","first-page":"ofae325","DOI":"10.1093\/ofid\/ofae325","volume":"11","author":"GY Callado","year":"2024","unstructured":"Callado GY, Salinas JL, Marra AR. The Obsolescence of Azithromycin for Syphilis Treatment and the Value of Contrasting Different Types of Evidence. Open Forum Infect Dis. 2024;11(7):ofae325.","journal-title":"Open Forum Infect Dis"},{"key":"725_CR66","doi-asserted-by":"crossref","unstructured":"Cannon CA, Menza TW, Reid TB, Lieberman NAP, Giacani L, Greninger AL. Comment on Callado et al: \"Syphilis Treatment: Systematic Review and Meta-analysis Investigating Nonpenicillin Therapeutic Strategies\". Open Forum Infect Dis. 2024;11(7):ofae324.","DOI":"10.1093\/ofid\/ofae324"},{"issue":"6","key":"725_CR67","first-page":"CD007270","volume":"2012","author":"ZG Bai","year":"2012","unstructured":"Bai ZG, Wang B, Yang K, Tian JH, Ma B, Liu Y, et al. Azithromycin versus penicillin G benzathine for early syphilis. Cochrane Database Syst Rev. 2012;2012(6):CD007270.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"725_CR68","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa040216","volume":"351","author":"SA Lukehart","year":"2004","unstructured":"Lukehart SA, Godornes C, Molini BJ, Sonnett P, Hopkins S, Mulcahy F, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med. 2004;351(2):154\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"725_CR69","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1086\/498899","volume":"42","author":"SJ Mitchell","year":"2006","unstructured":"Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes C, Klausner JD. Azithromycin-resistant syphilis infection: San Francisco, California, 2000\u20132004. Clin Infect Dis. 2006;42(3):337\u201345.","journal-title":"Clin Infect Dis"},{"key":"725_CR70","doi-asserted-by":"crossref","unstructured":"Cato K, Chuang E, Connolly KL, Deal C, Hiltke T. Summary of the national institute of allergy and infectious diseases workshop on alternative therapies to penicillin for the treatment of syphilis. Sex Transm Dis.\u00a0Published Online November 29, 2024.","DOI":"10.1097\/OLQ.0000000000002113"},{"key":"725_CR71","doi-asserted-by":"crossref","unstructured":"Villarreal DD, Le J, Klausner JD. Congenital syphilis - comprehensive narrative review of alternative antibiotic treatment for use in neonates. Sex Transm Dis. 2024;51:775\u2013779.","DOI":"10.1097\/OLQ.0000000000002057"},{"issue":"10","key":"725_CR72","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/OLQ.0000000000001050","volume":"46","author":"CP Roberts","year":"2019","unstructured":"Roberts CP, Raich A, Stafylis C, Klausner JD. Alternative Treatments for Syphilis During Pregnancy. Sex Transm Dis. 2019;46(10):637\u201340.","journal-title":"Sex Transm Dis"},{"issue":"1","key":"725_CR73","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archderm.1970.04000070080012","volume":"102","author":"NJ Fiumara","year":"1970","unstructured":"Fiumara NJ, Lessell S. Manifestations of late congenital syphilis. An analysis of 271 patients. Arch Dermatol. 1970;102(1):78\u201383.","journal-title":"Arch Dermatol."},{"issue":"3","key":"725_CR74","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/OLQ.0000000000001739","volume":"50","author":"LC Tantalo","year":"2023","unstructured":"Tantalo LC, Molini BJ, Bose M, Klausner JD, Giacani L. In Vitro Isolation of Treponema pallidum subsp. pallidum from fresh and frozen needle aspirates of primary experimental syphilis lesions. Sexually Transmitted Diseases. 2023;50(3):180\u20133.","journal-title":"Sexually Transmitted Diseases"},{"key":"725_CR75","doi-asserted-by":"crossref","unstructured":"Hayes KA, Dressler JM, Norris SJ, Edmondson DG, Jutras BL. A large screen identifies beta-lactam antibiotics which can be repurposed to target the syphilis agent. NPJ Antimicrob Resist. 2023;1:4.","DOI":"10.1038\/s44259-023-00006-3"},{"key":"725_CR76","doi-asserted-by":"crossref","unstructured":"Edmondson DG, Hu B, Norris SJ. Long-term In Vitro culture of the syphilis spirochete treponema pallidum subsp. pallidum. mBio. 2018;9:e01153\u201318. Published 2018 Jun 26.","DOI":"10.1128\/mBio.01153-18"},{"issue":"4","key":"725_CR77","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1473-3099(23)00693-X","volume":"24","author":"C Stafylis","year":"2024","unstructured":"Stafylis C, Klausner JD. Repurposing antibiotics to treat syphilis. Lancet Infect Dis. 2024;24(4):335\u20136.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"725_CR78","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/cid\/ciab187","volume":"73","author":"C Stafylis","year":"2021","unstructured":"Stafylis C, Keith K, Mehta S, Tellalian D, Burian P, Millner C, et al. Clinical Efficacy of Cefixime for the Treatment of Early Syphilis. Clin Infect Dis. 2021;73(5):907\u201310.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"725_CR79","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12879-020-04980-1","volume":"20","author":"MM Taylor","year":"2020","unstructured":"Taylor MM, Kara EO, Araujo MAL, Silveira MF, Miranda AE, Branco Coelho IC, et al. Phase II trial evaluating the clinical efficacy of cefixime for treatment of active syphilis in non-pregnant women in Brazil (CeBra). BMC Infect Dis. 2020;20(1):405.","journal-title":"BMC Infect Dis"},{"key":"725_CR80","unstructured":"Pei Xiaoyan YY, Zhao Wei, Zhang Yuan, Li Zhen, Wen Jing, Tian Hongqing. Assessment of the efficacy of oral cefixime for the treatment of early symptomatic syphilis. China Journal of Leprosy and Skin Diseases. 2021;37(6):373\u20135."},{"issue":"1","key":"725_CR81","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1186\/s13063-020-04885-z","volume":"21","author":"SN Mehta","year":"2020","unstructured":"Mehta SN, Stafylis C, Tellalian DM, Burian PL, Okada CM, Millner CE, et al. Clinical trial protocol to evaluate the efficacy of cefixime in the treatment of early syphilis. Trials. 2020;21(1):1009.","journal-title":"Trials"},{"key":"725_CR82","unstructured":"Wilson G, Keith K, Stafylis C, Konda KA, Reyes-Diaz M, Klausner JD. Comparing cefixime and penicillin G for early syphilis: rapid plasma reagin titer decline and preliminary treatment outcomes [Conference Abstract]. Accepted to STI and HIV World Congress Meeting 2025.\u00a0Authors made abstract available prior to publication."},{"issue":"4","key":"725_CR83","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1473-3099(23)00683-7","volume":"24","author":"M Ubals","year":"2024","unstructured":"Ubals M, Nadal-Baron P, Arando M, Rivero \u00c1, Mendoza A, DescalzoJorro V, et al. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2024;24(4):404\u201316.","journal-title":"Lancet Infect Dis"},{"key":"725_CR84","doi-asserted-by":"publisher","first-page":"103281","DOI":"10.1016\/j.ebiom.2021.103281","volume":"65","author":"AM Haynes","year":"2021","unstructured":"Haynes AM, Giacani L, Mayans MV, Ubals M, Nieto C, P\u00e9rez-Ma\u00f1\u00e1 C, et al. Efficacy of linezolid on Treponema pallidum, the syphilis agent: A preclinical study. EBioMedicine. 2021;65:103281.","journal-title":"EBioMedicine"},{"key":"725_CR85","doi-asserted-by":"crossref","unstructured":"Navarro S, Keith K, Stafylis C, Konda K, Klausner J. A review of the safety of linezolid during pregnancy, a potential alternative syphilis treatment. Sex Transm Dis.\u00a02023;50:e37\u2013e40.","DOI":"10.1097\/OLQ.0000000000001860"},{"key":"725_CR86","doi-asserted-by":"crossref","unstructured":"Stafylis C, Nguyen RM, Konda K, Reyes-Diaz M, Keith K, Warren E, et al. P-1378.\u00a0Linezolid for early syphilis treatment: pilot study, open forum infectious diseases. 2025;12 Supp 1:ofae631.1554.","DOI":"10.1093\/ofid\/ofae631.1554"},{"key":"725_CR87","doi-asserted-by":"crossref","unstructured":"Hook EW, Workowski K, Dionne JA, McNeil CJ, Taylor SN, Teresa B, et al. 2889.\u00a0One vs three weekly doses of benzathine penicillin G for treatment of early syphilis in persons with and without HIV: a multicenter Randomized Controlled Trial (RCT). Open Forum Infect Dis. 2023;10 Suppl 2:ofad500.2472.","DOI":"10.1093\/ofid\/ofad500.2472"},{"issue":"6","key":"725_CR88","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/cid\/ciw862","volume":"64","author":"R Andrade","year":"2017","unstructured":"Andrade R, Rodriguez-Barradas MC, Yasukawa K, Villarreal E, Ross M, Serpa JA. Single Dose Versus 3 Doses of Intramuscular Benzathine Penicillin for Early Syphilis in HIV: A Randomized Clinical Trial. Clin Infect Dis. 2017;64(6):759\u201364.","journal-title":"Clin Infect Dis"},{"key":"725_CR89","unstructured":"Hunt T, Berzkalns A, Cannon C, Dombrowski J, Golden M.\u00a0Observational comparison of three treatment regimens for late latent\/unknown stage syphilis (STIs) [Conference abstract]. Sex Health. 2024;21:SHv21n4abs."},{"issue":"2 Pt 2","key":"725_CR90","first-page":"143","volume":"3","author":"HW Jaffe","year":"1976","unstructured":"Jaffe HW. Treatment of latent syphilis. J Am Vener Dis Assoc. 1976;3(2 Pt 2):143\u20135.","journal-title":"J Am Vener Dis Assoc"},{"key":"725_CR91","doi-asserted-by":"publisher","first-page":"1131921","DOI":"10.3389\/fmed.2023.1131921","volume":"10","author":"HF Mi","year":"2023","unstructured":"Mi HF, Shen X, Chen XQ, Zhang XL, Ke WJ, Xiao Y. Association between treatment failure in patients with early syphilis and penicillin resistance-related gene mutations of. Front Med (Lausanne). 2023;10:1131921.","journal-title":"Front Med (Lausanne)"},{"key":"725_CR92","doi-asserted-by":"crossref","unstructured":"Chen KH, Sun HY, Chen CH, Chuang YC, Huang YS, Liu WD, et al.\u00a0Higher serologic responses of early syphilis to single-dose benzathine penicillin G plus doxycycline versus single-dose benzathine penicillin G alone among people with HIV.\u00a0Clin Infect Dis: an official publication of the Infectious Diseases Society of America. 2024;79:1308\u20131315.","DOI":"10.1093\/cid\/ciad508"},{"key":"725_CR93","doi-asserted-by":"crossref","unstructured":"Hla TK, Salman S, Kado J, Moore BR, Manning L.\u00a0Could late-latent syphilis be treated with a single subcutaneous infusion of long-acting penicillin?. Sex Health. 2024;21:SH24003.","DOI":"10.1071\/SH24003"},{"issue":"7","key":"725_CR94","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/0956462420984695","volume":"32","author":"H Wu","year":"2021","unstructured":"Wu H, Qi M, Wang H, Liu Q, Liu Y. Efficacy of minocycline in the treatment of early syphilis. Int J STD AIDS. 2021;32(7):648\u201353.","journal-title":"Int J STD AIDS"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00725-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-025-00725-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00725-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:07:04Z","timestamp":1769605624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-025-00725-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1007\/s11904-025-00725-4","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"1 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human or animal studies performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"22"}}